Anixa Biosciences (NASDAQ:ANIX – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03, FiscalAI reports.
Anixa Biosciences Stock Performance
Shares of NASDAQ ANIX traded down $0.05 during midday trading on Wednesday, hitting $2.35. 111,095 shares of the company’s stock traded hands, compared to its average volume of 139,785. The firm has a fifty day moving average of $2.79 and a 200 day moving average of $3.13. Anixa Biosciences has a 1 year low of $2.35 and a 1 year high of $5.46. The stock has a market capitalization of $78.80 million, a price-to-earnings ratio of -7.12 and a beta of 0.59.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in ANIX. Bank of America Corp DE grew its holdings in Anixa Biosciences by 1.7% during the 3rd quarter. Bank of America Corp DE now owns 213,955 shares of the company’s stock valued at $706,000 after buying an additional 3,645 shares in the last quarter. Prosperity Wealth Management Inc. lifted its holdings in shares of Anixa Biosciences by 14.5% in the third quarter. Prosperity Wealth Management Inc. now owns 41,800 shares of the company’s stock worth $138,000 after buying an additional 5,300 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Anixa Biosciences by 2.1% during the fourth quarter. Geode Capital Management LLC now owns 350,915 shares of the company’s stock worth $1,095,000 after acquiring an additional 7,271 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in shares of Anixa Biosciences by 2,000.0% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after acquiring an additional 10,000 shares during the last quarter. Finally, NewEdge Advisors LLC purchased a new position in Anixa Biosciences during the second quarter valued at $33,000. 29.13% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
View Our Latest Analysis on ANIX
About Anixa Biosciences
Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.
In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.
Read More
- Five stocks we like better than Anixa Biosciences
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
